Andrew Hedin joined Fidelity Biosciences in 2010. Prior to Fidelity Biosciences, Mr. Hedin was an Associate at Leerink Swann in the strategy consulting division. At Leerink, Mr. Hedin advised pharmaceutical, biotech and medical device clients, with engagements focused on M&A strategy, due diligence, commercial opportunity assessments, clinical development strategy, product life cycle management, and competitive landscape analysis. His case work covered a variety of therapeutic areas, including neurology, oncology, cardiology, endocrinology and rheumatology.
Mr. Hedin is a graduate of the University of Pennsylvania, where he received his B.A. in Biological Basis of Behavior. While at Penn, he conducted research in the neuroscience department and also worked for the Penn Resiliency Project, an international NIMH-funded study.